Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | SHR3680 |
| Synonyms | |
| Therapy Description |
SHR3680 is an androgen receptor antagonist with potential anti-tumor activity (PMID: 35241087). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| SHR3680 | Rezvilutamide|SHR 3680 | Hormone - Anti-androgens 58 | SHR3680 is an androgen receptor antagonist with potential anti-tumor activity (PMID: 35241087). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07611110 | Phase III | Cabazitaxel Darolutamide Radium Ra 223 dichloride SHR3680 Apalutamide FPI-2265 Abiraterone Enzalutamide HC-1119 | AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01) (VECTRA-01) | Recruiting | USA | TUR | GBR | FRA | ESP | DEU | CAN | BRA | AUT | AUS | 6 |